Power Alley Stuff: What Pfizer Is Bending Congressional -- And Regulatory Agency -- Ears About... To the Tune Of Over $10 Million This Year...

And, as promised -- here is the nearly $10.2 million -- through three quarters of 2025 -- by category, that Pfizer has spent. . . jaw-boning Congress and the agencies that regulate it.

As we said last night, the non-election years see it outspend Merck, as a rule:

. . .Vaccine Policy, Coverage and Access; HR 4317 - PMB Reform Act of 2025; Gavi Vaccines Alliance Issues; HR 2214 - DRUG Act; S 832 - EPIC Act of 2025; S 864 - HELP Copays ACT; S 882 - Patients Before Middlemen Act; Prescription Drug-Use-Related Software (PDURS): Digital Medicine; Lyme Disease Issues; Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; IRA Biosimilars Pause Fix, Biosimilar Legislation; H.R. 5256 - 340B Access ACT; Inflation Reduction Act (IRA): Orphan Drug Exemption, Pill Penalty, Biosimilar Pause; Vaccine Coverage and Access; Drug Pricing. . . .

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; PBM Reform; S 1702 - Access to Prescription Digital Therapeutics Act of 2025; Digital Therapeutics. . . .

International Supply Chain; Global Access; Most Favored Nation Policies; Tariffs; Non-Tariff Trade Barriers; United States-Mexico-Canada Agreement (USMCA). . . .

Onward, grinning, now you know -- out, for an annual physical and then picking up baby-girl -- for a live music show downtown tonight! Woot!

नमस्ते